T1	Intervention 341 350	tamoxifen
T2	Intervention 351 393	and to assess the therapeutic advantage of
T3	Intervention 394 406	sequentially
T4	Intervention 408 510	dding low-dose cyclophosphamide-methotrexate-5-fluorouracil (CMF) chemotherapy in tamoxifen responders
